A new study reveals a possible way to make CAR T-cell therapy more durable and effective by targeting a single ...

In a phase 1 study, anti-CD7 chimeric antigen receptor (CAR) T cells induced complete remission in children and adults with relapsed or refractory T-cell acute lymphoblastic leukemia (ALL), with 82% ...

At age 49, Jan Janisch-Hanzlik's multiple sclerosis was destroying her freedom to live the life she wanted. She gave up her ...

Please provide your email address to receive an email when new articles are posted on . CAR T-cell therapy for cancer may be associated with new-onset autoimmune disease. Autoimmune events in after ...

New approach recruits the body’s immune system to attack glioblastoma while reducing treatment-related toxicity.

CD7 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy in relapsed or refractory T-cell acute lymphoblastic leukemia (ALL). Supportive results of first-in-human studies of base ...

A laboratory study out of Roswell Park Comprehensive Cancer Center outlines a new way to boost the effectiveness of chimeric antigen receptor (CAR) T-cell therapy in solid-tumor cancers, resulting in ...

A bone marrow transplant can buy time for people with aggressive B-cell cancers. Too often, it does not buy enough. For patients whose disease returns after an allogeneic stem cell transplant, the ...

Scientists at the UCLA Health Jonsson Comprehensive Cancer Center have developed a new cytokine-armored CAR-T cell therapy ...